Glaukos Corp (N:GKOS)

Business Focus: Medical Devices & Implants

Aug 13, 2019 12:32 pm ET
TRCB, AVDR, CBM, and NCI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Two River Bancorp (NASDAQ GM: TRCB) regarding possible breaches of fiduciary duties and other violations of law related to Two River’s agreement to be acquired by OceanFirst Financial...
Aug 08, 2019 02:03 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Avedro, Inc.
NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Avedro, Inc. (NASDAQ: AVDR) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Glaukos Corporation (NYSE: GKOS). Stockholders will receive 0.365 shares of Glaukos Corporation common stock for each share of Avedro, Inc. stock that they hold. The transaction is valued at approximately $395 million and is expected to close in the fourth quarter of 2019....
Aug 08, 2019 11:32 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Avedro, Inc. to Glaukos Corporation is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Avedro, Inc. (“Avedro” or the “Company”) (NASDAQGM: AVDR) stock prior to August 7, 2019. You are hereby notified that Levi & Korsinsky,...
Aug 07, 2019 04:15 pm ET
Glaukos Corporation Announces Second Quarter 2019 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2019. Key highlights include:
Aug 07, 2019 04:10 pm ET
Glaukos and Avedro Announce Definitive Acquisition Agreement
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc. (Nasdaq: AVDR), a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders, today announced that the companies have entered into a definitive merger agreement under which Glaukos will acquire Avedro in an all-stock transaction. The transaction, which is subject to Avedro stockholder approval along with other customary closin
Jul 22, 2019 07:00 am ET
Glaukos Announces Global Licensing Agreement With Intratus, Inc.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related
Jul 22, 2019 07:00 am ET
Glaukos Corporation to Release Second Quarter 2019 Financial Results after Market Close on August 7
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2019 financial results after the market close on Wednesday, August 7, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 7, 2019.
Jun 27, 2019 04:15 pm ET
Glaukos Corporation Completes Acquisition of DOSE Medical Corporation
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has successfully completed the acquisition of DOSE Medical Corporation that was previously announced on June 19, 2019. With the transaction’s completion, DOSE Medical has now become a wholly owned subsidiary of Glaukos.
Jun 19, 2019 04:15 pm ET
Glaukos Corporation Enters into Definitive Agreement to Acquire DOSE Medical Corporation
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has entered into a definitive Agreement and Plan of Merger to acquire DOSE Medical Corporation (DOSE Medical) for $2.5 million in cash, plus performance-based consideration upon achievement of certain regulatory approvals and commercial milestones. Upon the consummation of the acquisition, DOSE Medical wil
Jun 04, 2019 04:15 pm ET
International Study Confirms Significant, Sustained IOP and Medication Reduction Following Standalone Implantation of Glaukos’ iStent inject® in Glaucoma Patients with Substantial Disease Burden
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an independent, international study published in Advances in Therapy showed standalone implantation of the iStent inject® Trabecular Micro-Bypass System in eyes with substantial glaucoma disease burden achieved a 42% reduct
May 22, 2019 04:15 pm ET
Glaukos Announces Participation in William Blair Growth Stock Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the William Blair Growth Stock Conference on Wednesday, June 5, 2019, at 8:00 a.m. CDT in Chicago, IL.
May 08, 2019 04:10 pm ET
Glaukos Corporation Announces First Quarter 2019 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the first quarter ended March 31, 2019. Key highlights include:
May 01, 2019 04:15 pm ET
Multiple Surgeons to Present Data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that numerous surgeons will present clinical trial and real-world data regarding it products at the American Society of Cataract and Refractory Surgery (ASCRS) Annual Meeting on May 3-7, 2019 at the San Diego Convention Center in downtown San Diego, CA.
Apr 30, 2019 07:00 am ET
Glaukos Announces Participation in Bank of America Merrill Lynch 2019 Health Care Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019, at 3:40 p.m. PDT in Las Vegas, Nevada.
Apr 26, 2019 03:05 am ET
Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States
Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) and Glaukos Corporation (“Glaukos” NYSE: GKOS), announced today that Santen’s U.S. subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt (development code: DE-128) solely in the U.S. market.
Apr 17, 2019 04:15 pm ET
Glaukos Corporation to Release First Quarter 2019 Financial Results after Market Close on May 8
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release first quarter 2019 financial results after the market close on Wednesday, May 8, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 8, 2019.
Apr 15, 2019 07:00 am ET
Prospective, Randomized Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents® vs. Topical Prostaglandin in Newly Diagnosed Glaucoma Patients
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent® Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35
Apr 01, 2019 07:15 am ET
New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics — Factors of Influence, Major Initiatives and S
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fresh Del Monte Produce, Inc. (NYSE:FDP), Baker Hughes, a GE company...
Mar 15, 2019 07:00 am ET
Pivotal Trial Results for Glaukos’ iStent inject® Published in Leading Ophthalmic Journal
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that the U.S. Investigational Device Exemption (IDE) pivotal trial results for its next-generation iStent inject® Trabecular Micro-Bypass System have been published in Ophthalmology.
Mar 13, 2019 04:15 pm ET
Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Glaucoma Society (AGS) Annual Meeting on March 14-17, 2019 at the Marriott Marquis Hotel in San Francisco.
Mar 12, 2019 04:15 pm ET
International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent® Implantation in Combination with Cataract Surgery
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent® Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean intraocular pr
Feb 27, 2019 04:10 pm ET
Glaukos Corporation Announces Fourth Quarter and Full Year 2018 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the fourth quarter and full year ended December 31, 2018. Key highlights include:
Feb 06, 2019 04:15 pm ET
Glaukos Corporation to Release Fourth Quarter and Full Year 2018 Financial Results after Market Close on February 27
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release fourth quarter and full year 2018 financial results after the market close on Wednesday, February 27, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 27, 2019.
Dec 19, 2018 04:15 pm ET
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 9:30 a.m. PST in San Francisco.
Dec 11, 2018 04:15 pm ET
Glaukos iStent inject® Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burden, According to New Study
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that a single-site international study of glaucoma subjects recently published in
Nov 27, 2018 07:45 am ET
Consolidated Research: 2018 Summary Expectations for The Hackett Group, Green Plains, Malibu Boats, Hawaiian Electric Industries, Iridium Communications, and Glaukos — Fundamental Analysis, Key Perfor
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Hackett Group, Inc. (NASDAQ:HCKT), Green Plains, Inc. (NASDAQ:GPRE),...
Nov 14, 2018 04:15 pm ET
Glaukos Announces Participation in Piper Jaffray Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 10:00 a.m. EST in New York City.
Nov 07, 2018 04:10 pm ET
Glaukos Corporation Announces Third Quarter 2018 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the third quarter ended September 30, 2018. Key highlights include:
Oct 26, 2018 07:00 am ET
Glaukos Technologies Featured in Presentations at 2018 American Academy of Ophthalmology Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Academy of Ophthalmology (AAO) Annual Meeting on October 27-30, 2018 at McCormick Place in Chicago, IL.
Oct 17, 2018 07:00 am ET
Glaukos Corporation to Release Third Quarter 2018 Financial Results after Market Close on November 7
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release third quarter 2018 financial results after the market close on Wednesday, November 7, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on November 7, 2018.
Oct 15, 2018 08:10 am ET
Detailed Research: Economic Perspectives on DDR, Acuity Brands, Douglas Emmett, Glaukos, US Ecology, and Lear — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DDR Corp. (NYSE:DDR), Acuity Brands Inc (NYSE:AYI), Douglas Emmett, Inc....
Sep 21, 2018 07:00 am ET
Multiple Surgeon Presentations to Showcase Glaukos Products at 2018 European Society of Cataract and Refractive Surgeons Congress
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be included in various physician presentations at the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) on September 22-26, 2018, at the Messe Wien Exhibition and Congress Center in Vienna, Austria.
Aug 22, 2018 04:15 pm ET
Glaukos Announces Participation in Wells Fargo Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 5, 2018, at 1:15 p.m. EDT in Boston, MA.
Aug 14, 2018 07:40 am ET
Investor Expectations to Drive Momentum within American Vanguard, Glaukos, United Natural Foods, Walker & Dunlop, Unisys, and Comfort Systems — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American Vanguard Corporation (NYSE:AVD), Glaukos Corporation (NYSE:GKOS),...
Aug 02, 2018 04:15 pm ET
Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide.
Aug 02, 2018 04:15 pm ET
Glaukos Corporation Announces Second Quarter 2018 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the second quarter ended June 30, 2018. Key highlights include:
Jul 19, 2018 07:00 am ET
Glaukos Corporation to Release Second Quarter 2018 Financial Results after Market Close on August 2
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release second quarter 2018 financial results after the market close on Thursday, August 2, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 2, 2018.
Jun 25, 2018 07:00 am ET
Glaukos Announces FDA Approval for the iStent inject® Trabecular Micro-Bypass System
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the iStent inject® Trabecular Micro-Bypass System indicated for the reduction of intraocular pressure (IOP) in adult mild-to-moderate primary ope
May 30, 2018 04:15 pm ET
Glaukos Announces Participation in William Blair Growth Stock Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the William Blair Growth Stock Conference on Tuesday, June 12, 2018, at 2:50 p.m. CDT in Chicago, IL.
May 16, 2018 08:20 am ET
New Research Coverage Highlights Ellie Mae, Micron Technology, Applied Optoelectronics, Acadia Realty Trust, Glaukos, and Noble Energy — Consolidated Revenues, Company Growth, and Expectations for 201
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie Mae, Inc. (NYSE:ELLI), Micron Technology, Inc. (NASDAQ:MU), Applied...
May 09, 2018 04:15 pm ET
Glaukos Corporation Announces First Quarter 2018 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the first quarter ended March 31, 2018. Key highlights include:
May 02, 2018 07:00 am ET
Glaukos Announces Participation in Bank of America Merrill Lynch 2018 Health Care Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018, at 3:00 p.m. PDT in Las Vegas, Nevada.
Apr 19, 2018 04:30 pm ET
Glaukos Corporation to Release First Quarter 2018 Financial Results after Market Close on May 9
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release first quarter 2018 financial results after the market close on Wednesday, May 9, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 9, 2018.
Apr 14, 2018 03:30 pm ET
IDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that two-year U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent inject® Trabecular Micro-Bypass System achieved a statistically significant reduction in unmedicated diurnal intraocular pressure (IOP) in patients undergoing cataract surgery.
Apr 14, 2018 08:00 am ET
Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has filed a patent infringement lawsuit against Ivantis, Inc. in the U.S. District Court for the Central District of California, Southern Division. The lawsuit alleges that Ivantis’ Hydrus Microstent device infringes Glaukos patents relating to certain of Glaukos’ core glaucoma technologies.
Apr 11, 2018 07:00 am ET
Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be included in various physician presentations at the American Society of Catara
Mar 02, 2018 07:00 am ET
Glaukos Announces Participation in 30th Annual ROTH Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 30th Annual ROTH Conference on Monday, March 12, 2018, at 10:00 a.m. PDT in Laguna Niguel, California.
Feb 28, 2018 04:10 pm ET
Glaukos Corporation Announces Fourth Quarter and Full Year 2017 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the fourth quarter and full year ended December 31, 2017. Key highlights include:
Feb 27, 2018 04:30 pm ET
Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be featured in numerous presentations at the 28th Annual Meeting of t
Feb 27, 2018 07:00 am ET
International Study Shows Long-Term Titrated IOP Control with 1, 2 or 3 Glaukos iStent® Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that, according to a study published in Clinical Ophthalmology, implantation of one, two or three iStent® Trabecular Micro-Bypass Stents achieved mean unmedicated intraocular pressure (IOP) reductions of 30%, 37% and 43%, respectively, at 36 months postoperative.
Feb 13, 2018 08:10 am ET
Detailed Research: Economic Perspectives on Omega Healthcare Investors, Vanda Pharmaceuticals, Acushnet, Prospect Capital, Intercontinental Exchange, and Glaukos — What Drives Growth in Today's Compet
NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Omega Healthcare Investors, Inc. (NYSE:OHI), Vanda...
Feb 08, 2018 07:00 am ET
Glaukos iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New Study
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published in the January 2018 issue of the
Feb 07, 2018 07:00 am ET
Glaukos Corporation to Release Fourth Quarter and Full Year 2017 Financial Results after Market Close on February 28
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release fourth quarter and full year 2017 financial results after the market close on Wednesday, February 28, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 28, 2018.
Jan 10, 2018 07:00 am ET
Glaukos Corporation’s iDose™ Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its Travoprost Intraocular Implant with the iDose™ delivery system continued to provide sustained reduction in intraocular pressure (IOP) in a 12-month interim cohort of patients in its U.S. Investigational New Drug (IND) Phase II clinical trial.
Jan 03, 2018 07:00 am ET
Glaukos Submits IDE Application to FDA to Study iStent infinite™ Trabecular Micro-Bypass System
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking authorization to study its iStent infinite™ Trabecular Micro-Bypass System.
Dec 27, 2017 04:30 pm ET
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018, at 9:00 a.m. PST in San Francisco.
Dec 27, 2017 07:00 am ET
Glaukos Announces Submission of Pre-Market Approval Application for the iStent Inject® Trabecular Micro-Bypass
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the iStent inject® Trabecular Micro-Bypass Stent.
Dec 19, 2017 07:00 am ET
Glaukos to Begin Randomized U.S. IDE Pivotal Clinical Trial for the iStent SA™ System
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that the U.S. Food and Drug Administration (FDA) is allowing the company to move forward with a U.S. Investigational Device Exemption (IDE) pivotal study of its iStent SA™ Trabecular Micro-Bypass System.
Nov 30, 2017 07:00 am ET
Glaukos Announces Issuance of New U.S. Patent
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 9,827,143 to the company.
Nov 27, 2017 07:30 am ET
Research Report Identifies Walker & Dunlop, Vanda Pharmaceuticals, Acushnet, SS&C Technologies, ManpowerGroup, and Glaukos with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Walker & Dunlop, Inc. (NYSE:WD), Vanda...
Nov 07, 2017 04:15 pm ET
Glaukos Corporation Announces Third Quarter 2017 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the third quarter ended September 30, 2017. Key highlights include:
Oct 31, 2017 07:00 am ET
Glaukos Announces Participation in Stifel 2017 Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017, at 10:15 a.m. EST in New York City.
Oct 24, 2017 07:00 am ET
Glaukos Corporation to Release Third Quarter 2017 Financial Results after Market Close on November 7
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release third quarter 2017 financial results after the market close on Tuesday, November 7, 2017. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on November 7, 2017.
Oct 05, 2017 04:45 pm ET
Glaukos iStent® Products to be Showcased at 2017 European Society of Cataract and Refractive Surgery
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that various Key Opinion Leader (KOL) presentations and electronic posters will feature its iStent® Trabecular Micro-Bypass and iStent inject® Trabecular Micro-Bypass products at the upcoming European Society of Cataract and Refractive Surgery (ESCRS) annual